Any adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Induction of endoscopic remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Quality‐of‐life scores with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Serious adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC
It is very uncertain whether fecal microbiota transplantation changes serious adverse events with use of FMT for induction of remission in… compared with control (very low certainty).
1 finding from 1 review
Any adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC
Fecal microbiota transplantation showed no clear difference in any adverse events with use of FMT for induction of remission in UC… compared with control (low certainty).
1 finding from 1 review
Induction of endoscopic remission in UC at longest · people with active UC
Fecal microbiota transplantation showed no clear difference in induction of endoscopic remission in UC at longest compared with control (low certainty).
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Short‐Form 36 health survey (SF‐36) · Patients with active Crohn's disease
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical response compared with placebo cigarettes (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found